BPC-157 dosage: chart, reported range and vial math

How to mix a BPC-157 vial

These steps are for the 5 mg vial picked in the chart. Change the size there and the amounts here change with it.

1. Wash your hands. Wipe the stopper of the peptide vial and the water vial with an alcohol swab.
2. Draw 2 mL of bacteriostatic water into a syringe.
3. Push the needle through the stopper of the peptide vial and let the water run slowly down the glass, not straight onto the powder.
4. Swirl the vial gently until the powder is gone. Do not shake it.
5. Write the date and 2.5 mg/mL on the vial, then put it in the fridge.

What BPC-157 is

BPC-157 is a synthetic peptide of 15 amino acids (a pentadecapeptide) that was originally isolated from gastric juice. No approved medicine containing it was found in the US or Canada. [5]

Other names: BPC 157, BPC157, Body Protection Compound 157, PL 14736, PL-10, PLD-116, Bepecin, PCO-02.

How it has been given to people: In the published human reports: injection into the knee joint, injection into the bladder wall during cystoscopy, and intravenous infusion. No published human study of injection under the skin was found.

What to know before reading a dose

• No approved product was found in the US or Canada. Every human dose on record comes from three small reports with the same first author [1], [2], [3], covering 2 to 16 patients each and none injected under the skin.
• The knee report is described two ways: its abstract says 11 of 12 improved [1]; a later systematic review says 7 of 12 had relief beyond 6 months [4]. The abstract gives no dose.
• FDA no longer lists BPC-157 in category 2. Its page, current as of 22 April 2026, shows it under substances previously in category 2 whose nominations were withdrawn [13], and the 14 May 2026 category list does not contain it [14]. Statements that it is on the Category 2 list are out of date.
• WADA names BPC-157 on the 2026 Prohibited List under S0 Non-approved substances, prohibited at all times [16].
• Health Canada names BPC-157 as an unauthorized injectable peptide drug in advisory RA-81874 of 9 April 2026 [17].
• The claim that BPC-157 was shown safe in human bowel disease trials rests on passing mentions in animal papers [7]. No report of those trials was found.

Doses on record for BPC-157

Every dose below was given in a human study or printed on an approved label, and each links to its source. Doses set by body weight are left that way.

What the evidence shows

Each finding is tagged by the kind of study it comes from. Human trials are listed first.

Side effects and warnings

Reported in human studies or on a label:

• No side effects were reported by the 2 people given intravenous infusions. [3]
• No adverse events were reported among the 12 women in the bladder injection pilot. [2]
• A 2025 systematic review found no clinical safety data. [4]
• The same review warns that harm is possible from unregulated manufacturing, contamination or unknown clinical safety. [4]
• FDA says compounded BPC-157 may carry a risk of immune reactions for some routes of administration. [13]
• FDA says it does not have enough information to know whether BPC-157 would cause harm in humans. [13]

BPC-157 has no approved label in the US or Canada for this use, so there is no official list of who should not use it, no interaction list and no missed-dose rule.

Storage

Keep an unmixed vial the way its label says. Once it is mixed, keep it in the fridge, do not freeze it, and write the mixing date on the vial.

BPC-157 dosage questions

Sources

Each one was opened on 10 Oct 2026 and matched to the line it supports.

1. Lee E et al. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med 2021. PubMed 34324435.
2. Lee E et al. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med 2024. PubMed 39325560.
3. Lee E et al. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med 2025. PubMed 40131143.
4. Vasireddi N et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J 2025. PubMed 40756949.
5. McGuire FP et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med 2025. PubMed 40789979.
6. He L et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol 2022. PubMed 36588717.
7. Sikiric P et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology 2006. PubMed 17186181.
8. Staresinic M et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res 2003. PubMed 14554208.
9. Bicer O et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg 2026. PubMed 42542926.
10. PCO-02 - Safety and Pharmacokinetics Trial ClinicalTrials.gov 2015. clinicaltrials.gov. Trial NCT02637284.
11. Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery ClinicalTrials.gov 2026. clinicaltrials.gov. Trial NCT07803250.
12. BPC 157 for Acute Hamstring Muscle Strain Repair ClinicalTrials.gov 2026. clinicaltrials.gov. Trial NCT07437547.
13. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks US Food and Drug Administration 2026. fda.gov.
14. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act US Food and Drug Administration 2026. fda.gov.
15. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act US Food and Drug Administration 2026. fda.gov.
16. World Anti-Doping Code International Standard Prohibited List 2026 World Anti-Doping Agency 2026. wada-ama.org.
17. Think twice before injecting peptides bought online: unauthorized products can seriously harm you Health Canada 2026. recalls-rappels.canada.ca.
18. TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD ClinicalTrials.gov 2026. clinicaltrials.gov. Trial NCT07487363.

Looked for and not found

• No approved product or label in the US or Canada, so no official dose, contraindications, interaction list, missed-dose rule or storage instructions.
• No published human study of BPC-157 injected under the skin. PubMed was searched for BPC-157 with patients, volunteers, clinical trial, case report, pilot and retrospective.
• No human half-life. The only pharmacokinetic study found is in rats and dogs [6].
• The dose injected into the knee in [1] is not stated in the abstract.
• No PubMed record reporting the PL 14736 inflammatory bowel disease trials themselves. They are mentioned only in passing in animal papers [7].
• No results or publication for the oral Phase 1 study NCT02637284 [10]. It was registered in 2015 to give healthy volunteers tablets containing 1 mg each (single doses of 1, 3 or 6 tablets, then 3 tablets every 8 hours for 2 weeks). Its status is listed as unknown, so these are planned doses, not doses known to have been given.
• No completed trial of injection under the skin. A university pilot ([11], daily injections for 90 days after rotator cuff repair) had not started recruiting when checked and its record gives no dose in mg. A second record ([12], daily injections for 14 days) also gives no dose; see flags.
• Human study of BPC-157 given together with TB-500 or thymosin beta-4: one PubMed search (BPC-157 with TB-500 or thymosin terms) returned 12 records; the only human data are the 4 knee patients in [1]. No trial was found.

Change log

Related

TB-500 dosageKPV dosageARA-290 dosageMGF dosageCartalax dosage5 mg vial10 mg vialWhat BPC-157 isHealing and recoveryPeptide dosage chartDosage calculator

DosageFacts is an information site. It is not medical advice. Talk to a licensed professional before using any medication.